GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Steep Hill Inc (XCNQ:STPH) » Definitions » EBITDA Margin %

Steep Hill (XCNQ:STPH) EBITDA Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Steep Hill EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Steep Hill's EBITDA for the three months ended in Dec. 2023 was C$-0.01 Mil. Steep Hill's Revenue for the three months ended in Dec. 2023 was C$0.00 Mil. Therefore, Steep Hill's EBITDA margin for the quarter that ended in Dec. 2023 was 0.00%.


Steep Hill EBITDA Margin % Historical Data

The historical data trend for Steep Hill's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Steep Hill EBITDA Margin % Chart

Steep Hill Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
- - -422.79 -317.70 -

Steep Hill Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -216.26 - - - -

Competitive Comparison of Steep Hill's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Steep Hill's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Steep Hill's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Steep Hill's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Steep Hill's EBITDA Margin % falls into.



Steep Hill EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Steep Hill's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-0.445/0
= %

Steep Hill's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-0.011/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Steep Hill  (XCNQ:STPH) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Steep Hill EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Steep Hill's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Steep Hill (XCNQ:STPH) Business Description

Traded in Other Exchanges
N/A
Address
120 Adelaide Street West, Suite 2500, Toronto, ON, CAN, M5H 1T1
Steep Hill Inc is a science and technology health and wellness company focused on the hemp markets inclusive of plant-based, psychedelic pharmaceutical and non-psychedelic nutraceutical, and hemp cannabinoids (CBD) verticals. Currently the company, through its subsidiaries holds three industrial hemp licences for the purposes of supplying the global market with medicinal and wellness cannabidiol and other cannabinoid-based products.

Steep Hill (XCNQ:STPH) Headlines

No Headlines